Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2018 Jan 16;10(1):97.
doi: 10.3390/nu10010097.

Specific Collagen Peptides Improve Bone Mineral Density and Bone Markers in Postmenopausal Women-A Randomized Controlled Study

Free PMC article
Clinical Trial

Specific Collagen Peptides Improve Bone Mineral Density and Bone Markers in Postmenopausal Women-A Randomized Controlled Study

Daniel König et al. Nutrients. .
Free PMC article


Introduction: Investigations in rodents as well as in vitro experiments have suggested an anabolic influence of specific collagen peptides (SCP) on bone formation and bone mineral density (BMD). The goal of the study was to investigate the effect of 12-month daily oral administration of 5 g SCP vs. placebo (CG: control group) on BMD in postmenopausal women with primary, age-related reduction in BMD. Methods: 131 women were enrolled in this randomized, placebo-controlled double-blinded investigation. The primary endpoint was the change in BMD of the femoral neck and the spine after 12 months. In addition, plasma levels of bone markers-amino-terminal propeptide of type I collagen (P1NP) and C-telopeptide of type I collagen (CTX 1)-were analysed. Results: A total of 102 women completed the study, but all subjects were included in the intention-to-treat (ITT) analysis (age 64.3 ± 7.2 years; Body Mass Index, BMI 23.6 ± 3.6 kg/m²; T-score spine -2.4 ± 0.6; T-score femoral neck -1.4 ± 0.5). In the SCP group (n = 66), BMD of the spine and of the femoral neck increased significantly compared to the control group (n = 65) (T-score spine: SCP +0.1 ± 0.26; CG -0.03 ± 0.18; ANCOVA p = 0.030; T-score femoral neck: SCP +0.09 ± 0.24; CG -0.01 ± 0.19; ANCOVA p = 0.003). P1NP increased significantly in the SCP group (p = 0.007), whereas CTX 1 increased significantly in the control group (p = 0.011). Conclusions: These data demonstrate that the intake of SCP increased BMD in postmenopausal women with primary, age-related reduction of BMD. In addition, SCP supplementation was associated with a favorable shift in bone markers, indicating increased bone formation and reduced bone degradation.

Keywords: SCP; bone marker; collagen hydrolysate; osteoporosis; protein supplementation.

Conflict of interest statement

Daniel König, Steffen Oesser, Stephan Scharla, Denise Zdzieblik and Albert Gollhofer declare that they have no conflict of interest.


Figure 1
Figure 1
Flow diagram of patient recruitment, randomization and follow up.
Figure 2
Figure 2
Procedure of the clinical trial and points of examinations. BMD, bone mineral density; DXA, dual energy X-ray absorptiometry.
Figure 3
Figure 3
Changes in bone mineral density at the end of the study (ΔBMD X12-X0). The data represent mean ± SEM, * ANCOVA statistically significantly different. SCP = specific collagen peptides.

Similar articles

See all similar articles

Cited by 8 articles

See all "Cited by" articles


    1. Hernlund E., Svedbom A., Ivergard M., Compston J., Cooper C., Stenmark J., McCloskey E.V., Jönsson B., Kanis J.A. Osteoporosis in the European Union: Medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA) Arch. Osteoporos. 2013;8:136. doi: 10.1007/s11657-013-0136-1. - DOI - PMC - PubMed
    1. Kreutle V., Blum C., Meier C., Past M., Müller B., Schütz P., Borm K. Bisphosphonate induced hypocalcaemia - report of six cases and review of the literature. Swiss Med. Wkly. 2014;144:w13979. doi: 10.4414/smw.2014.13979. - DOI - PubMed
    1. Kaehling C., Streckbein P., Schmermund D., Henrich M., Burchert D., Gattenloehner S., Howaldt H.P., Wilbrand J.F. Lethal cervical abscess following bisphosphonate related osteonecrosis of the jaw. J. Cranio-Maxillofac. Surg. 2014;42:1203–1206. doi: 10.1016/j.jcms.2014.02.009. - DOI - PubMed
    1. Rachner T.D., Platzbecker U., Felsenberg D., Hofbauer L.C. Osteonecrosis of the jaw after osteoporosis therapy with denosumab following long-term bisphosphonate therapy. Mayo Clin. Proc. 2013;88:418–419. doi: 10.1016/j.mayocp.2013.01.002. - DOI - PubMed
    1. Montagnani A. Bone anabolics in osteoporosis: Actuality and perspectives. World J. Orthop. 2014;5:247–254. doi: 10.5312/wjo.v5.i3.247. - DOI - PMC - PubMed

Publication types

MeSH terms